LPA and coronary artery disorder: Randomized controlled trials of Lp(a) lowering are now required to assess whether this reduces both low-attenuation plaque progression and cardiovascular events.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: In patients with advanced coronary artery disease, elevated serum Lp(a) is associated with accelerated progression of the low-attenuation necrotic core of atherosclerotic plaques.